These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22890270)

  • 21. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates.
    Abonnenc M; Sonego G; Crettaz D; Aliotta A; Prudent M; Tissot JD; Lion N
    Transfusion; 2015 Sep; 55(9):2219-30. PubMed ID: 25873361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates.
    Nebie O; Devos D; Vingtdeux V; Barro L; Devedjian JC; Jonneaux A; Chou ML; Bordet R; Buée L; Knutson F; Blum D; Burnouf T
    J Biomed Sci; 2019 Oct; 26(1):89. PubMed ID: 31666073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen.
    Cazenave JP; Aleil B; Wiesel ML; Laforêt M; Isola H
    Vox Sang; 2004 Apr; 86(3):201-2. PubMed ID: 15078258
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage.
    Cancelas JA; Genthe JR; Stolla M; Rugg N; Bailey SL; Nestheide S; Shaz B; Mack S; Schroeder K; Anani W; Szczepiorkowski ZM; Dumont LJ; Yegneswaran S; Corash L; Mufti N; Benjamin RJ; Erickson AC
    Transfusion; 2022 Aug; 62(8):1619-1629. PubMed ID: 35808974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation.
    Picker SM; Speer R; Gathof BS
    Transfusion; 2004 Mar; 44(3):320-9. PubMed ID: 14996187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of amotosalen plus ultraviolet A-mediated pathogen reduction for all platelet concentrates in France: Impact on the risk of transfusion-transmitted infections.
    Richard P; Pouchol E; Sandid I; Aoustin L; Lefort C; Chartois AG; Baima A; Malard L; Bacquet C; Ferrera-Tourenc V; Gallian P; Laperche S; Bliem C; Morel P; Tiberghien P
    Vox Sang; 2024 Mar; 119(3):212-218. PubMed ID: 38152857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
    BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogen inactivation treatment of triple-dose apheresis platelets with amotosalen and ultraviolet a light.
    Infanti L; Pehlic V; Mitrovic S; Holbro A; Andresen S; Payrat JM; Lin JS; Buser A
    Transfus Med; 2022 Dec; 32(6):505-511. PubMed ID: 36124649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haemostatic responsiveness and release of biological response modifiers following cryopreservation of platelets treated with amotosalen and ultraviolet A light.
    Tynngård N; Wikman A; Uhlin M; Sandgren P
    Blood Transfus; 2020 May; 18(3):191-199. PubMed ID: 31403931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6
    Erickson A; Waldhaus K; David T; Huang N; Rico S; Corash L; Mufti N; Benjamin RJ
    Transfusion; 2017 Apr; 57(4):997-1006. PubMed ID: 28150310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease.
    Castro G; Merkel PA; Giclas HE; Gibula A; Andersen GE; Corash LM; Lin JS; Green J; Knight V; Stassinopoulos A
    Transfusion; 2018 Jun; 58(6):1506-1515. PubMed ID: 29607502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro.
    Van Aelst B; Feys HB; Devloo R; Vanhoorelbeke K; Vandekerckhove P; Compernolle V
    Vox Sang; 2015 May; 108(4):328-39. PubMed ID: 25557250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.
    Lozano M; Galan A; Mazzara R; Corash L; Escolar G
    Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.
    Rosskopf K; Helmberg W; Schlenke P
    Transfusion; 2020 Sep; 60(9):2058-2066. PubMed ID: 32619068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.
    Knutson F; Osselaer J; Pierelli L; Lozano M; Cid J; Tardivel R; Garraud O; Hervig T; Domanovic D; Cukjati M; Gudmundson S; Hjalmarsdottir IB; Castrillo A; Gonzalez R; Brihante D; Santos M; Schlenke P; Elliott A; Lin JS; Tappe D; Stassinopoulos A; Green J; Corash L
    Vox Sang; 2015 Nov; 109(4):343-52. PubMed ID: 25981525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.
    Amato M; Schennach H; Astl M; Chen CY; Lin JS; Benjamin RJ; Nussbaumer W
    Vox Sang; 2017 Jan; 112(1):47-55. PubMed ID: 28001297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
    Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L
    Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increase of Phosphoprotein Expressions in Amotosalen/UVA-Treated Platelet Concentrates.
    Muret C; Crettaz D; Alberio L; Prudent M
    Transfus Med Hemother; 2024 Apr; 51(2):101-110. PubMed ID: 38584699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system.
    Johnson L; Loh YS; Kwok M; Marks DC
    Transfus Med; 2013 Apr; 23(2):121-9. PubMed ID: 23480103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.